UNITED THERAPEUTICS currently trades with a PEG ratio of 2.3, based on Jun 23, 2026 data. Dividing the 18.59 PE ratio by the 8.1% earnings growth rate produces this figure. Relative to the 1.26 average from the past 4 quarters, the PEG ratio has surged by 83%.
Historically, UNITED THERAPEUTICS maintains a PEG ratio averaging 0.68 across the last ten years. At 2.3, today's PEG ratio sits 238% higher than its historical average. The ten years high came in the Mar 2023 quarter at 3.62, reflecting peak valuation relative to growth. The bottom was reached in the Jun 2016 quarter at 0.01, suggesting favorable value relative to growth during that period.
| Year | PEG ratio | PE ratio | Growth YoY |
|---|---|---|---|
| 2025 | 1.16 | 16.17 | 14% |
| 2024 | 0.52 | 13.34 | 25.7% |
| 2023 | 0.33 | 10.45 | 31.7% |
| 2022 | 0.34 | 17.4 | 50.8% |
| 2021 | N/A | 20.38 | -9% |
| 2020 | 0.02 | 13.03 | 587.4% |
| 2019 | N/A | N/A | -117.7% |
| 2018 | 0.19 | 8.04 | 42.5% |
| 2017 | N/A | 15.57 | -41.7% |
| 2016 | 0.59 | 8.8 | 15% |
| 2015 | 0.11 | 11.05 | 100.7% |
| 2014 | 0.18 | 18.34 | 102.3% |
| 2013 | N/A | 32.4 | -40.2% |
| 2012 | 0.17 | 9.15 | 53.3% |
| 2011 | 0.12 | 12.4 | 101.6% |
| Year | PEG ratio | PE ratio | Growth YoY |
|---|---|---|---|
| Mar 2026 | 2.5 | 20.25 | 8.1% |
| Dec 2025 | 1.16 | 16.17 | 14% |
| Sep 2025 | 0.86 | 14.72 | 17.2% |
| Jun 2025 | 0.52 | 10.38 | 19.9% |
| Mar 2025 | 0.54 | 11.38 | 21.1% |
| Dec 2024 | 0.52 | 13.34 | 25.7% |
| Sep 2024 | 0.56 | 14.74 | 26.1% |
| Jun 2024 | 0.61 | 13.8 | 22.6% |
| Mar 2024 | 0.25 | 10.27 | 41% |
| Dec 2023 | 0.33 | 10.45 | 31.7% |
| Sep 2023 | 0.5 | 11.72 | 23.5% |
| Jun 2023 | 0.34 | 11.72 | 34.8% |
| Mar 2023 | 3.62 | 14.12 | 3.9% |
| Dec 2022 | 0.34 | 17.4 | 50.8% |
| Sep 2022 | 0.26 | 13.41 | 51.3% |
UTHR's PEG ratio today is above the 3, 5 and 10-year averages.
With a PEG of 2.3, UTHR ranks higher than the Healthcare sector and the industry average. In comparison with the Healthcare sector average of 0.56, UNITED THERAPEUTICS's PEG is 311% higher.
Relative to its peers, UTHR's PEG ratio is below CAH's yet above LLY's and GILD's.
| Stock name | PEG ratio | Market cap |
|---|---|---|
| TEVA Teva Pharmaceutical Industries Ltd | 0.11 | $38.67B |
| GILD Gilead Sciences Inc | 0.3 | $155.26B |
| LLY ELI LILLY & Co | 0.31 | $1.04T |
| UTHR UNITED THERAPEUTICS Corp | 2.3 | $23.11B |
| CAH Cardinal Health Inc | 17.42 | $53.61B |
| PFE Pfizer Inc | N/A | $140.89B |
| BAX Baxter International Inc | N/A | $10.38B |
| CYTK Cytokinetics Inc | N/A | $9.96B |
According to Jun 23, 2026 figures, UTHR's PEG ratio stands at 2.3.
Historical data over a 3-year period puts UTHR's average PEG ratio at 0.72.
Historical data over a 5-year period puts UTHR's average PEG ratio at 0.88.
UTHR's PEG ratio topped out at 3.62 during the Mar 2023 quarter - the highest in ten years.
Compared to the 10-year average, UTHR's PEG ratio sits 238% higher.
A 2.3 PEG ratio for UTHR suggests the stock trades at a premium relative to its growth trajectory.
Computing the PEG ratio involves dividing the PE ratio by the company's EPS growth rate (YoY TTM). As of Jun 23, 2026, UNITED THERAPEUTICS carries a PE ratio of 18.59. Earnings grew at 8.1% over the TTM period ending Mar 2026. Applying the formula, this yields a PEG ratio of 2.3. PEG RATIO(2.3) = PE RATIO(18.59) / EPS GROWTH(8.1%)
All PEG ratio stats are based on quarterly TTM periods, unless otherwise specified.